Franklin M. Berger Acquires 25,000 Shares of Immune Design Corp. (IMDZ) Stock
Immune Design Corp. (NASDAQ:IMDZ) Director Franklin M. Berger purchased 25,000 shares of Immune Design Corp. stock in a transaction on Wednesday, October 25th. The shares were acquired at an average cost of $4.26 per share, with a total value of $106,500.00. Following the completion of the transaction, the director now directly owns 50,000 shares in the company, valued at approximately $213,000. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of Immune Design Corp. (IMDZ) opened at 4.10 on Friday. The stock’s 50 day moving average is $9.49 and its 200-day moving average is $8.54. Immune Design Corp. has a 52 week low of $3.78 and a 52 week high of $13.05. The firm’s market cap is $105.04 million.
Immune Design Corp. (NASDAQ:IMDZ) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.11. Immune Design Corp. had a negative return on equity of 59.14% and a negative net margin of 324.33%. The company had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $1.50 million. On average, equities analysts predict that Immune Design Corp. will post ($2.29) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/10/28/franklin-m-berger-acquires-25000-shares-of-immune-design-corp-imdz-stock.html.
Institutional investors have recently added to or reduced their stakes in the company. State of Wisconsin Investment Board purchased a new stake in shares of Immune Design Corp. during the second quarter worth approximately $117,000. Alliancebernstein L.P. purchased a new stake in shares of Immune Design Corp. during the second quarter worth approximately $118,000. Bank of America Corp DE raised its stake in shares of Immune Design Corp. by 123.3% during the first quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 8,418 shares during the last quarter. Virtu KCG Holdings LLC purchased a new stake in shares of Immune Design Corp. during the second quarter worth approximately $153,000. Finally, Dimensional Fund Advisors LP raised its stake in shares of Immune Design Corp. by 9.3% during the second quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock worth $184,000 after purchasing an additional 1,600 shares during the last quarter. Institutional investors and hedge funds own 51.47% of the company’s stock.
A number of equities analysts have issued reports on the stock. BidaskClub lowered shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. Royal Bank Of Canada assumed coverage on shares of Immune Design Corp. in a research report on Thursday, September 14th. They set an “outperform” rating and a $20.00 price target for the company. ValuEngine raised shares of Immune Design Corp. from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Zacks Investment Research raised shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Tuesday, July 18th. Finally, Wells Fargo & Company lowered shares of Immune Design Corp. from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $29.00 to $10.00 in a research report on Tuesday, October 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $14.75.
Immune Design Corp. Company Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Stock Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related stocks with our FREE daily email newsletter.